Hallo, liebe Mitstreiter!
Eine Studie in Bush-Country hat gezeigt, dass die Einnahme des Osteoporose-Medikaments Raloxifene (Evista) das Risiko, an "Brustkrebs und anderen Krebsarten" zu erkranken, halbiert (siehe Veröffentlichung unten). Das Medikament blockiert offensichtlich die für das Ausbreiten des Krebses entscheidenden Östrogen-Rezeptoren.
Ich weiß nicht, ob und inwieweit das für uns von Interesse sein könnte, aber die Parallelen zwischen Brust- und Prostatakrebs als hormoninduzierte Krebsarten werden ja immer wieder betont.
Schorschel
Hier der Text aus dem Medizin-Dienst „Ivanhoe“:
„Reported June 11, 2008
Osteoporosis Drug Prevents Breast Cancer
By Kirsten Houmann, Ivanhoe Health Correspondent
ffice:smarttags" />Fla.
A study at theUniversity of California at San Diego
“This is great because a lot of women have bone issues, and may be at a high risk for getting an invasive breast cancer,” Dr. Black said. “This medicine is a safe medicine that can prevent breast cancer.”
Raloxifene is a selective estrogen receptor modulator (SERM), which means it has estrogen-like effects on tissues like bone, but anti-estrogen effects on tissues like breast tissue. Most post-menopausal women with breast cancer have invasive, ER positive breast cancer. When breast cancer is invasive, it has started to break through normal breast tissue barriers and invade surrounding areas. ER positive, or hormone responsive, means the breast cancer grows when it comes in contact with estrogen.
“We now have medicines, such as Evista, that can sit on that estrogen receptor and block that receptor so that estrogen cannot get on [it],” Dalliah Mashon Black, M.D., a breast surgeon at theHoffberger Breast Center at Mercy Medical Center in Baltimore
The study was conducted as a follow-up to the Raloxifene Use for the Heart Trial (RUTH), the world’s largest study of women and heart disease to date. The trial found raloxifene did not protect against heart disease, but did reduce the risk of invasive breast cancer by 44 percent.
According to the National Cancer Institute, 182,460 new cases of breast cancer in women will be diagnosed in 2008.”
SOURCE: Journal of the National Cancer Institute, 2008; published online June 10th
Eine Studie in Bush-Country hat gezeigt, dass die Einnahme des Osteoporose-Medikaments Raloxifene (Evista) das Risiko, an "Brustkrebs und anderen Krebsarten" zu erkranken, halbiert (siehe Veröffentlichung unten). Das Medikament blockiert offensichtlich die für das Ausbreiten des Krebses entscheidenden Östrogen-Rezeptoren.
Ich weiß nicht, ob und inwieweit das für uns von Interesse sein könnte, aber die Parallelen zwischen Brust- und Prostatakrebs als hormoninduzierte Krebsarten werden ja immer wieder betont.
Schorschel
Hier der Text aus dem Medizin-Dienst „Ivanhoe“:
„Reported June 11, 2008
Osteoporosis Drug Prevents Breast Cancer
By Kirsten Houmann, Ivanhoe Health Correspondent
ffice:smarttags" />
A study at the
“This is great because a lot of women have bone issues, and may be at a high risk for getting an invasive breast cancer,” Dr. Black said. “This medicine is a safe medicine that can prevent breast cancer.”
Raloxifene is a selective estrogen receptor modulator (SERM), which means it has estrogen-like effects on tissues like bone, but anti-estrogen effects on tissues like breast tissue. Most post-menopausal women with breast cancer have invasive, ER positive breast cancer. When breast cancer is invasive, it has started to break through normal breast tissue barriers and invade surrounding areas. ER positive, or hormone responsive, means the breast cancer grows when it comes in contact with estrogen.
“We now have medicines, such as Evista, that can sit on that estrogen receptor and block that receptor so that estrogen cannot get on [it],” Dalliah Mashon Black, M.D., a breast surgeon at the
The study was conducted as a follow-up to the Raloxifene Use for the Heart Trial (RUTH), the world’s largest study of women and heart disease to date. The trial found raloxifene did not protect against heart disease, but did reduce the risk of invasive breast cancer by 44 percent.
According to the National Cancer Institute, 182,460 new cases of breast cancer in women will be diagnosed in 2008.”
SOURCE: Journal of the National Cancer Institute, 2008; published online June 10th
Kommentar